Study finds tradeoffs in canine point-of-care troponin testing

A newly published AJVR study adds fresh evidence on an increasingly practical question in small animal medicine: how well an in-clinic troponin I test performs when veterinarians need to detect meaningful cardiac injury in dogs without waiting on a reference lab. According to the article title and abstract summary, the Vcheck cardiac troponin I assay showed acceptable performance for detecting clinically important canine myocardial injury, but its precision dropped at low concentrations, where interpretation is often hardest. The work was led by Bobbie Ditzler, Ashley B. Saunders, and Sonya R. Wesselowski and appeared among AJVR’s most recent articles on October 14, 2026. (vetlit.org)

That finding lands in a diagnostic space that’s been evolving for years. Cardiac troponin I is considered a gold-standard biomarker for myocardial injury in dogs, and because canine and human troponin I are highly homologous, human-platform assays have often been adapted for veterinary use after validation. But assay-specific performance matters. Earlier work has shown that different analyzers can produce proportional bias or different low-end behavior, which means clinicians can’t assume one troponin result is interchangeable with another across platforms. (pmc.ncbi.nlm.nih.gov)

The source study compared the Vcheck point-of-care assay with the ADVIA Centaur XP High-Sensitivity Troponin I assay, an established chemiluminescent laboratory method. The underlying samples were surplus canine serum collected from a diagnostic laboratory between September 4, 2024, and August 21, 2025. While the full article details weren’t fully accessible in the search results, the reported conclusion is directionally clear: the point-of-care assay appears capable of flagging dogs with clinically important myocardial injury, but its lower-concentration performance is weaker, which limits confidence in subtle elevations or near-normal readings. (vetlit.org)

That low-end limitation is consistent with what the field has already seen. In a 2023 validation study involving the ADVIA Centaur XP high-sensitivity assay in dogs, Wesselowski and colleagues found the assay measured canine cTnI accurately and reproducibly above 20 pg/mL, but repeatability was poorer below that threshold, even though many dogs had measurable values at lower levels. The authors concluded the assay remained clinically useful because dogs with overt myocardial injury would generally be expected to have concentrations well above that range. In other words, the hardest zone is often not the clearly sick dog, but the dog with a mild, equivocal, or early increase. (pmc.ncbi.nlm.nih.gov)

Other recent evidence points in the same direction for point-of-care platforms more broadly. A 2024 study on the i-STAT cTnI assay reported agreement with common commercial laboratory assays in dogs and cats with suspected myocardial injury, suggesting bedside troponin testing can be clinically useful when rapid answers matter. But a separate 2026 study in Doberman Pinschers found the Vcheck V200 cTnI assay had lower diagnostic accuracy than a laboratory-based IDEXX troponin assay, especially for early-stage disease detection, even though it still offered practical in-clinic value and helped identify dogs that warranted fuller cardiac workups. (pubmed.ncbi.nlm.nih.gov)

There doesn’t appear to be substantial outside commentary on the new AJVR paper yet, but the broader expert message has been fairly consistent: troponin is useful, fast testing is valuable, and platform validation is essential. Prior analytical studies have explicitly warned that not all commercial troponin assays perform equally across species, and that species- and assay-specific characterization is needed to avoid misinterpretation. That’s especially relevant for general practice, emergency, and specialty teams that may be tempted to treat all troponin numbers as directly comparable. (pubmed.ncbi.nlm.nih.gov)

Why it matters: For veterinary professionals, this study supports a pragmatic middle ground. A point-of-care troponin assay may be good enough to strengthen suspicion of meaningful myocardial injury in dogs when time matters, including emergency presentations, suspected myocarditis, arrhythmia workups, trauma cases, or peri-anesthetic concern. But reduced precision at low concentrations means clinicians should be careful not to over-interpret small increases, small serial changes, or values near the assay’s lower end. In practice, that likely means using point-of-care troponin as part of a layered decision process, not as a standalone answer, and confirming borderline findings with a validated laboratory assay when the result could change treatment, referral, or prognosis discussions with a pet parent. (pmc.ncbi.nlm.nih.gov)

What to watch: The next things worth watching are the paper’s full analytical tables, any proposed clinical cutoffs for “clinically important” injury, and whether follow-on studies test the assay prospectively in real-world emergency or cardiology patients rather than stored serum alone. It will also be important to see whether future work defines when Vcheck is best used for rule-in testing, screening, serial monitoring, or referral triage. (vetlit.org)